CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...

Lexeo says the collaboration will accelerate the development of an unnamed preclinical cardiac gene therapy target.

NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...